BIOV Bioventus Inc. Class A Common Stock (MM)

Cytokine Biomarkers and Antibody Panels Introduced For Sale GAITHERSBURG, Md., Feb. 13 /PRNewswire-FirstCall/ -- BioVeris Corporation (NASDAQ:BIOV) announced today that it has introduced for sale eight new products for use in life science research. These new products are focused on meeting the increasing demand among pharmaceutical and biotechnology companies for a means to measure potential immune response to protein-based therapeutics that are in development. Two of the new products are pharmacodynamic biomarkers designed to measure cytokine levels that may be elevated in response to a drug treatment. These cytokine products detect human IL-2 and TNF-alpha, molecules that are up- regulated in inflammation and in many immune responses. Six of the new products can be used for immunogenicity testing, assay development, and hybridoma screening. These products compose a panel of antibodies that are prelabeled with BioVeris' detection label BV-TAG(TM) Plus and may be used to quantitate and characterize the following mouse antibodies: IgM, IgG, IgG1, IgG2a, IgG2b, and IgG3. BioVeris' Contract Services Organization will also add the new products to its test menu and offer more testing options for its biopharma customers. More information on these products, including product specification sheets and application notes, is available on BioVeris' website at http://www.bioveris.com/. BioVeris' life science products can be used by pharmaceutical and biotechnology companies, universities, and other contract research organizations (CRO) throughout most phases of drug discovery and development, including: -- validating targets identified through genomics; -- screening large numbers of compounds generated through combinatorial chemistry; -- re-testing and optimization of lead compounds; and -- nonclinical and clinical trial testing of drug candidates. Pharmaceutical and biotechnology companies and regulatory agencies are increasingly concerned about a patient's potential immune response to a protein-based therapeutic and they are attempting to screen out those molecules as early in development as possible. All of BioVeris' new products should be useful in these phases of drug development. The new products were developed to provide excellent sensitivity and dynamic range to customers, using more rapid and easier methods than competitive products on the market. Immunogenicity testing is performed by pharmaceutical and biotechnology companies in order to characterize the ability of protein-based therapeutics to stimulate an immune response. Antibodies that result from an immune response to a protein-based drug can reduce its efficacy and cause significant side effects, such as allergic reactions. Because of serious side effects that have been reported, it has become increasingly necessary to determine if an immune response to protein-based drugs develops in patients by screening for the presence of antibodies, confirming their specificity, characterizing the type of antibodies present and determining whether they interfere with binding events. Immunogenicity testing is done during pre-clinical studies and may continue through the clinical trials required for regulatory approval. In some cases, the FDA requires additional testing after a drug has been approved. BioVeris Corporation is a global health care and biosecurity company developing proprietary technologies in diagnostics and vaccinology. The Company is dedicated to the development and commercialization of innovative products and services for healthcare providers, their patients and their communities. BioVeris is headquartered in Gaithersburg, Maryland. Further information about BioVeris is available at http://www.bioveris.com/ . This press release contains forward-looking statements within the meaning of the federal securities laws that relate to future events or BioVeris' future financial performance. All statements in this press release that are not historical facts, including any statements about the markets, potential markets, market growth, the prospects for and utility of a new product in the market and the Company's ability to compete, are hereby identified as "forward-looking statements." The words "may," "should," "will," "expect," "could," "anticipate," "believe," "estimate," "plan," "intend" and similar expressions have been used to identify certain of the forward-looking statements. In this press release, BioVeris has based these forward-looking statements on management's current expectations, estimates and projections and they are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements should, therefore, be considered in light of various important factors, including changes in BioVeris' strategy and business plans; BioVeris' ability to develop and introduce new or enhanced products; the utility and customer acceptance of new products; the availability of financing and financial resources in the amounts, at the times and on the terms required to support BioVeris' future business; and changes in general economic, business and industry conditions. The foregoing sets forth some, but not all, of the factors that could impact upon BioVeris' ability to achieve results described in any forward-looking statements. A more complete description of the risks applicable to BioVeris is provided in the Company's filings with the Securities and Exchange Commission (SEC) available at the SEC's web site at http://www.sec.gov/ . Investors are cautioned not to place undue reliance on these forward-looking statements. Investors also should understand that is not possible to predict or identify all risk factors and that neither this list nor the factors identified in BioVeris' SEC filings should be considered a complete statement of all potential risks and uncertainties. BioVeris has no obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this press release. DATASOURCE: BioVeris Corporation CONTACT: George Migausky of BioVeris Corporation, +1-301-869-9800, ext. 2013; Media: Paul Caminiti or Andrew Cole of Sard Verbinnen & Co, +1-212-687-8080, for BioVeris Corporation; Investors: Jonathan Fassberg of The Trout Group, +1-212-477-9007, ext. 16, for BioVeris Corporation Web site: http://www.bioveris.com/

Copyright